Share on StockTwits

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Director Robert B. Rothermel purchased 5,500 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was purchased at an average cost of $4.03 per share, with a total value of $22,165.00. Following the purchase, the director now directly owns 20,000 shares in the company, valued at approximately $80,600. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) traded up 26.12% on Tuesday, hitting $5.07. The stock had a trading volume of 886,241 shares. Adamis Pharmaceuticals Corp has a one year low of $2.62 and a one year high of $11.90. The stock has a 50-day moving average of $3.74 and a 200-day moving average of $5.28. The company’s market cap is $53.2 million.

Separately, analysts at CRT Capital reiterated a “positive” rating on shares of Adamis Pharmaceuticals Corp in a research note on Tuesday, June 24th. They now have a $15.00 price target on the stock.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), formerly Cellegy Pharmaceuticals, Incoperates through its wholly owned subsidiaries Cellegy Holdings, Inc, Adamis Corporation and Biosyn, Inc Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc (Adamis Viral) and Adamis Laboratories, Inc (Adamis Labs).

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.